113. Muscular dystrophy Clinical trials / Disease details
Clinical trials : 622 / Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04433234 (ClinicalTrials.gov) | June 30, 2020 | 12/6/2020 | Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | A Phase II, Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Drug: DS-5141b | Daiichi Sankyo Co., Ltd. | NULL | Active, not recruiting | 5 Years | N/A | Male | 8 | Phase 2 | Japan |
| 2 | NCT02667483 (ClinicalTrials.gov) | October 2015 | 26/1/2016 | Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | Phase I/II Study of DS-5141b: Open-label Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Drug: DS-5141b | Daiichi Sankyo Co., Ltd. | Orphan Disease Treatment Institute Co., Ltd. | Active, not recruiting | 5 Years | 10 Years | Male | 7 | Phase 1/Phase 2 | Japan |